Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG
Waubant E, Banwell B, Wassmer E, Sormani M, Amato M, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T, Aaen G, Ben Adou E, Al-Roughani R, Alvarez V, Anagnostouli M, Anlar B, Armangue T, Arrambide G, Baroncini D, Bembeeva R, Benson L, Bizjak N, Blaschek A, Boyko A, Brenton J, Brück W, Klein da Costa B, Dive D, Elpers C, Filippi M, de Oliveira Fragomeni M, Havrdova E, Hemingway C, Kornek B, Deiva K, Lacy A, Liba Z, Lim M, Lotze T, Mah J, Makhani N, Mar S, McKay K, Menascu S, Moiola L, Mulero P, Ndiaye M, Neuteboom R, Ness J, Lobato de Oliveira E, Otallah S, Patti F, Albino da Paz J, Perez C, Pohl D, Ponsonby A, Rensel M, Rocca M, Rijke N, Rodriguez M, Rossman I, Sakuma H, Schreiner T, Schteinschnaider A, Sikes E, Simone I, Sweeney M, Tillema J, Troxell R, Verhelst H, Vilchez L, De Waele L, Weinstock-Guttman B, Wilbur C, Yann M, Yeh E, Zafeiriou D. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology 2019, 92: 10.1212/wnl.0000000000007572. PMID: 31043474, PMCID: PMC6556085, DOI: 10.1212/wnl.0000000000007572.Peer-Reviewed Original ResearchAdolescentChildClinical Trials as TopicEvidence-Based MedicineHumansMultiple Sclerosis, Relapsing-Remitting
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply